Tag:
subcutaneous drug delivery
Latest Headlines
Latest Headlines
Titan plans Q3 NDA submission for controlled-release implantable addiction treatment
Titan Pharmaceuticals ( $TTNP ) now envisions an NDA submission to the FDA for its implantable, controlled release treatment for opioid dependence during its fiscal 2012 third quarter. The South San...
Valeritas gets FDA nod for V-Go's use with NovoLog
Bridgewater, NJ-based Valeritas has cleared another regulatory hurdle. The venture-backed firm said this week it has garnered FDA clearance for its disposable system for subcutaneous delivery of Novo
Titan takes $5M loan for studies on opioid addiction treatment
South San Francisco-based Titan Pharmaceuticals is borrowing $5 million from Oxford Finance. It needs the money to continue its Phase III trials of Probuphine to treat opioid addiction. The device
